The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate
Open accessAbstract
The unique glycolytic metabolism of most solid tumors, known as the Warburg effect, is associated with resistance to apoptosis that enables cancer cells to survive. Dichloroacetate (DCA) is an anticancer agent that can reverse the Warburg effect by inhibiting a key enzyme in cancer cells, pyruvate dehydrogenase kinase (PDK), that is required for the process. DCA is currently not approved for cancer treatment in the USA. Here, we present the synthesis, characterization, and anticancer properties of c,t,c-[Pt(NH 3)2(O 2 CHCl 2)2 Cl 2], mitaplatin, in which two DCA units are appended to the axial positions of a six-coordinate Pt(IV) center. The negative intracellular redox potential reduces the platinum to release cisplatin, a Pt(II) compound, and two equivalents of DCA. By a unique mechanism, mitaplatin thereby attacks both nuclear DNA with cisplatin and mitochondria with DCA selectively in cancer cells. The cytotoxicity of mitaplatin in a variety of cancer cell lines equals or exceeds that of all known Pt(IV) compounds and is comparable to that of cisplatin. Mitaplatin alters the mitochondrial membrane potential gradient (Δψ m) of cancer cells, promoting apoptosis by releasing cytochrome c and translocating apoptosis inducing factor from mitochondria to the nucleus. Cisplatin formed upon cellular reduction of mitaplatin enters the nucleus and targets DNA to form 1,2-intrastrand d(GpG) cross-links characteristic of its own potency as an anticancer drug. These properties of mitaplatin are manifest in its ability to selectively kill cancer cells cocultured with normal fibroblasts and to partially overcome cisplatin resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425
Why Do Cancers Have High Aerobic Glycolysis?
Gatenby, R. A., & Gillies, R. J. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1478 · Cited by 4,784
Platinum Compounds: a New Class of Potent Antitumour Agents
ROSENBERG, B., VANCAMP, L., TROSKO, J. E., & MANSOUR, V. H. (1969) · Nature · doi:10.1038/222385a0 · Cited by 3,972
Cellular processing of platinum anticancer drugs
Wang, D., & Lippard, S. J. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1691 · Cited by 3,801
Self-citationCisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335
Structure, Recognition, and Processing of Cisplatin−DNA Adducts
Jamieson, E. R., & Lippard, S. J. (1999) · Chemical Reviews · doi:10.1021/cr980421n · Cited by 2,949
Self-citationBonnet, S., Archer, S. L., Allalunis-Turner, J., Haromy, A., Beaulieu, C., Thompson, R., Lee, C. T., Lopaschuk, G. D., Puttagunta, L., Bonnet, S., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.10.020 · Cited by 1,530
Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death
Joza, N., Susin, S. A., Daugas, E., Stanford, W. L., Cho, S. K., Li, C. Y. J., Sasaki, T., Elia, A. J., Cheng, H.-Y. M., Ravagnan, L., et al. (2001) · Nature · doi:10.1038/35069004 · Cited by 1,366
Cytochrome C -Mediated Apoptosis
Jiang, X., & Wang, X. (2004) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.73.011303.073706 · Cited by 1,357
Cancer's Molecular Sweet Tooth and the Warburg Effect
Kim, J.-W., & Dang, C. V. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1501 · Cited by 1,215
Cossarizza, A., Baccaranicontri, M., Kalashnikova, G., & Franceschi, C. (1993) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1993.2438 · Cited by 1,029
Dhar, S., Gu, F. X., Langer, R., Farokhzad, O. C., & Lippard, S. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809154105 · Cited by 994
Self-citationXu, R.-H., Pelicano, H., Zhou, Y., Carew, J. S., Feng, L., Bhalla, K. N., Keating, M. J., & Huang, P. (2005) · Cancer Research · doi:10.1158/0008-5472.613.65.2 · Cited by 835
Galanski, M. S., Jakupec, M. A., & Keppler, B. K. (2005) · Current Medicinal Chemistry · doi:10.2174/0929867054637626 · Cited by 721
Dhar, S., Liu, Z., Thomale, J., Dai, H., & Lippard, S. J. (2008) · Journal of the American Chemical Society · doi:10.1021/ja803036e · Cited by 700
Self-citationThe pharmacology of dichloroacetate
Stacpoole, P. W. (1989) · Metabolism · doi:10.1016/0026-0495(89)90051-6 · Cited by 484
Perego, P., Giarola, M., Righetti, S. C., Supino, R., Caserini, C., Delia, D., Pierotti, M. A., Miyashita, T., Reed, J. C., & Zunino, F. (1996) · PubMed · Cited by 384
Samudio, I., Fiegl, M., & Andreeff, M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3722 · Cited by 308
Connected to Death: The (Unexpurgated) Mitochondrial Pathway of Apoptosis
Spierings, D., McStay, G., Saleh, M., Bender, C., Chipuk, J., Maurer, U., & Green, D. R. (2005) · Science · doi:10.1126/science.1117105 · Cited by 299
Reduction and Anticancer Activity of Platinum(IV) Complexes
Choi, S., Filotto, C., Bisanzo, M., Delaney, S., Lagasee, D., Whitworth, J. L., Jusko, A., Li, C., Wood, N. A., Willingham, J., et al. (1998) · Inorganic Chemistry · doi:10.1021/ic971047x · Cited by 270
Controlled Clinical Trial of Dichloroacetate for Treatment of Congenital Lactic Acidosis in Children
Stacpoole, P. W., Kerr, D. S., Barnes, C., Bunch, S. T., Carney, P. R., Fennell, E. M., Felitsyn, N. M., Gilmore, R. L., Greer, M., Henderson, G. N., et al. (2006) · Pediatrics · doi:10.1542/peds.2005-1226 · Cited by 259
Giandomenico, C. M., Abrams, M. J., Murrer, B. A., Vollano, J. F., Rheinheimer, M. I., Wyer, S. B., Bossard, G. E., & Higgins, J. D. (1995) · Inorganic Chemistry · doi:10.1021/ic00109a004 · Cited by 248
Conjugated Platinum(IV)−Peptide Complexes for Targeting Angiogenic Tumor Vasculature
Mukhopadhyay, S., Barnés, C. M., Haskel, A., Short, S. M., Barnes, K. R., & Lippard, S. J. (2008) · Bioconjugate Chemistry · doi:10.1021/bc070031k · Cited by 226
Self-citationDichloroacetate induces apoptosis in endometrial cancer cells
Wong, J. Y. Y., Huggins, G. S., Debidda, M., Munshi, N. C., & De Vivo, I. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.01.038 · Cited by 219
Current Status and Future Prospects for Satraplatin, an Oral Platinum Analogue
Choy, H., Park, C., & Yao, M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2176 · Cited by 217
Mitochondria as a critical target of the chemotheraputic agent cisplatin in head and neck cancer
Cullen, K. J., Yang, Z., Schumaker, L., & Guo, Z. (2007) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-006-9059-5 · Cited by 194
Metabolic targeting of hypoxia and HIF1 in solid tumors can enhance cytotoxic chemotherapy
Cairns, R. A., Papandreou, I., Sutphin, P. D., & Denko, N. C. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611662104 · Cited by 182
Cao, W., Yacoub, S., Shiverick, K. T., Namiki, K., Sakai, Y., Porvasnik, S., Urbanek, C., & Rosser, C. J. (2008) · The Prostate · doi:10.1002/pros.20788 · Cited by 181
Characterization of a novel metabolic strategy used by drug‐resistant tumor cells
Harper, M., Antoniou, A., Villalobos‐Menuey, E., Russo, A., Trauger, R., Vendemelio, M., George, A., Bartholomew, R., Carlo, D., Shaikh, A., et al. (2002) · The FASEB Journal · doi:10.1096/fj.02-0541com · Cited by 172
Efficacy of Dichloroacetate as a Lactate-Lowering Drug
Stacpoole, P. W., Nagaraja, N. V., & Hutson, A. D. (2003) · Journal of Clinical Pharmacology · doi:10.1177/0091270003043007001 · Cited by 171
Resistance of Mitochondrial DNA-depleted Cells against Cell Death
Park, S. Y., Chang, I., Kim, J.-Y., Kang, S. W., Park, S.-H., Singh, K., & Lee, M.-S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m307677200 · Cited by 170
Hall, M. D., Dillon, C. T., Zhang, M., Beale, P. J., Cai, Z., Lai, B. C. H., Stampfl, A. P. J., & Hambley, T. W. (2003) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-003-0471-6 · Cited by 157
Mitochondria as cancer drug targets.
Don, A., & Hogg, P. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.06.005 · Cited by 146
Liedert, B. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl051 · Cited by 115
Floryk, D., & Houštěk, J. (1999) · Bioscience Reports · doi:10.1023/a:1020193906974 · Cited by 105
Revolution in mitochondrial medicine
Larsson, N., & Luft, R. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00854-6 · Cited by 81
Cancer patients opt for unapproved drug
Pearson, H. (2007) · Nature · doi:10.1038/446474a · Cited by 52
Cited by
Johnstone, T. C., Suntharalingam, K., & Lippard, S. J. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00597 · Cited by 2,485
Self-citationCisplatin: The first metal based anticancer drug
Ghosh, S. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.102925 · Cited by 1,751
Platinum-based drugs: past, present and future
Dilruba, S., & Kalayda, G. V. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-2976-z · Cited by 906
Metabolic Modulation of Glioblastoma with Dichloroacetate
Michelakis, E. D., Sutendra, G., Dromparis, P., Webster, L., Haromy, A., Niven, E., Maguire, C., Gammer, T.-L., Mackey, J. R., Fulton, D., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000677 · Cited by 720
Targeting and delivery of platinum-based anticancer drugs
Wang, X., & Guo, Z. (2013) · Chem. Soc. Rev. · doi:10.1039/c2cs35259a · Cited by 684
Metadata
- Authors
- Dhar, S., & Lippard, S. J.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2009-12-29
- Volume
- 106
- Issue
- 52
- Pages
- 22199-22204
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2090168914
- Cited by
- 369
- References
- 38
- FWCI
- 6.86
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.